TAMPA, Fla., March 31, 2026 (GLOBE NEWSWIRE) -- Inhibitor Therapeutics, Inc. (OTCQB: INTI) ("Inhibitor" or the "Company"), today provided an update on its ongoing pharmacokinetic (PK) clinical program ...
MORRISVILLE, N.C., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced it has entered into a Master Services Agreement (MSA) with Catalent, which ...
first biocompatible pharmaceutical formulations progress to preclinical models new sustained-release drug delivery platforms for peptides, melanocortins aim to predict drug release kinetics from new ...
BOSTON--(BUSINESS WIRE)--Elektrofi, a Boston-based biotechnology company focused on drug formulation and delivery innovations, today announced it has entered into a contract with the Defense Health ...
Nanoform (Finland), an innovative nanoparticle medicine enabling company, today announced it has signed a GMP 1 manufacturing program (clinical development) to enhance TargTex’s Glioblastoma ...
WOBURN, Mass.--(BUSINESS WIRE)--ReForm Biologics, a pharmaceutical technology company developing innovative biologic formulations to improve drug delivery and manufacturing, today announced a new ...
The first part of this paper lays out the process of program design and briefly describes some of the analytical tools--including the financial programming framework, the balance sheet approach, and ...
Company outlines near-term pharmacokinetic milestones, highlights amorphous formulation strategy, and announces planned global patent filing TAMPA, Fla., March 31, 2026 (GLOBE NEWSWIRE)-- Inhibitor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results